Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years

Authors

Institutions

Publication Details

Journal
Human Vaccines & Immunotherapeutics
Published
2026-05-29
DOI
https://doi.org/10.1080/21645515.2026.2675021
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years

Kimball Johnson, Lusiné Kostanyan, Rituparna Das, Melissa Sinkiewicz et al.
Human Vaccines & Immunotherapeutics
SARS-CoV-2 and COVID-19 Research
article

Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years

Kimball Johnson, Lusiné Kostanyan, Rituparna Das, Melissa Sinkiewicz, Jose Cardona, Iris Wu
article en

Abstract

No abstract available for this paper.
Human Vaccines & ImmunotherapeuticsVol. 22(1)
Moderna Therapeutics (United States) (US), iResearch Atlanta (US), University of Science and Technology Chittagong (BD)
Moderna
Good health and well-being
Openalex Percentile: Top 6%
SARS-CoV-2 and COVID-19 Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.